Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Response to additional drugs, including multitargeted tyrosine kinase inhibitors (in patients with SM, such as midostaurin) and anti-IgE therapy (omalizumab), may be considered an indirect sign of MCA or MCAS.
“Response to additional drugs, including multitargeted tyrosine kinase inhibitors (in patients with SM, such as midostaurin) and anti-IgE therapy (ie, omalizumab) may be considered an indirect sign of MCA or MCAS.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [81]
The PATIENT 1 and PATIENT 2 sections (page not available) report fewer or no anaphylaxis episodes after omalizumab in two patients with systemic mastocytosis. The paper does not present treatment response as an indirect sign of mast-cell activation or MCAS, and it does not address midostaurin or other multitargeted tyrosine kinase inhibitors. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., & Metzger, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412603 · Cited by 703 · see citing works
Omalizumab-induced reductions in mast cell FcεRI expression and function
Beck, L. A., Marcotte, G. V., MacGlashan, D., Togias, A. G., & Saini, S. S. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.032 · Cited by 456 · see citing works
Serum IgE Level Drives Basophil and Mast Cell IgE Receptor Display
MacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A. G., & Lichtenstein, L. M. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000237504 · Cited by 62 · see citing works
Robyn, J. A., & Metcalfe, D. D. (2006) · Advances in immunology · doi:10.1016/s0065-2776(05)89005-4 · Cited by 38 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Melody C. Carter, MD a Jamie A. Robyn, MD, PhD a Peter B. Bressler, MD b John C. Walker, MD c Gail G. Shapiro, MD d Dean D. Metcalfe, MD a From a the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Allergic Disease, Bethesda, Md; b Caro- lina Allergy and Asthma, Chapel Hill, NC; c the Northwest Allergy and Asthma Center, University of Washington Children's Hospital and Re- gional Medical Center, Richland, Wash; and d the Northwest Allergy and Asthma Center, University of Washington School of Medicine, Seattle, Wash. E-mail: mcarter@niaid.nih.gov. Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. Disclosure of potential conflict of interest: P. B. Bressler has received grant support from Genentech/Novartis and is on the speakers' bureau for Sanofi-Aventis, AstraZeneca, and Schering-Plough. The rest of the authors have declared that they have no conflict of interest. Editor's note: Readers interested in this topic may also be interested in a forthcoming Letter to the Editor in which Siebenhaar and colleagues pre- sent a case report of ''Successful treatment of cutaneous mastocytosis with anti-IgE.'' Look for this article in the July 2007 issue of the JACI, or ahead of print publication in the Articles in Press section of the JACI Web site, www.jacionline.org.
Cited by
Sorted by citations
Mast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518 · see citing works
The pathophysiology of anaphylaxis
Reber, L. L., Hernandez, J. D., & Galli, S. J. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.003 · Cited by 518 · see citing works
Simons, F. E. R. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.981 · Cited by 370 · see citing works
Anaphylaxis: A 2023 practice parameter update
Golden, D. B. K., Wang, J., Waserman, S., Akin, C., Campbell, R. L., Ellis, A. K., Greenhawt, M., Lang, D. M., Ledford, D. K., Lieberman, P., et al. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.09.015 · Cited by 383 · see citing works
Therapies for allergic inflammation: refining strategies to induce tolerance
Akdiş, C. A. (2012) · Nature Medicine · doi:10.1038/nm.2754 · Cited by 295 · see citing works
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Kaplan, A. P., Giménez‐Arnau, A. M., & Saini, S. S. (2016) · Allergy · doi:10.1111/all.13083 · Cited by 291 · see citing works
Mechanisms of mast cell signaling in anaphylaxis
Metcalfe, D. D., Peavy, R. D., & Gilfillan, A. M. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.035 · Cited by 283 · see citing works
Self-citationDiagnosis and management of anaphylaxis in precision medicine
Castells, M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.012 · Cited by 242 · see citing works
Anaphylaxis: Recent advances in assessment and treatment
Simons, F. E. R. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.025 · Cited by 241 · see citing works
Understanding the mechanisms of anaphylaxis
Peavy, R. D., & Metcalfe, D. D. (2008) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e3283036a90 · Cited by 211 · see citing works
Self-citationMast cell activation syndromes
Akin, C. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.007 · Cited by 178 · see citing works
Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy
Niedoszytko, M., de Monchy, J., van Doormaal, J. J., Jassem, E., & Elberink, J. N. G. O. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02118.x · Cited by 158 · see citing works
High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience
Gülen, T., Hägglund, H., Dahlén, B., & Nilsson, G. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12225 · Cited by 156 · see citing works
Human mast cells and basophils—How are they similar how are they different?
Varricchi, G., Raap, U., Rivellese, F., Marone, G., & Gibbs, B. F. (2018) · Immunological Reviews · doi:10.1111/imr.12627 · Cited by 151 · see citing works
Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers
Jiménez‐Rodriguez, T. W., Garcia-Neuer, M. I., Alenazy, L. A., & Castells, M. (2018) · Journal of Asthma and Allergy · doi:10.2147/jaa.s159411 · Cited by 152 · see citing works
González‐de‐Olano, D., Álvarez‐Twöse, I., Esteban‐López, M. I., Sánchez‐Muñoz, L., de Durana, M. D. A. D., Vega, A., García‐Montero, A. C., Gonzalez-Mancebo, E., Belver, M. T., Herrero-Gil, M. D., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.010 · Cited by 130 · see citing works
IgE-Related Chronic Diseases and Anti-IgE-Based Treatments
Navinés‐Ferrer, A., Serrano‐Candelas, E., Molina-Molina, G.-J., & Martı́n, M. (2016) · Journal of Immunology Research · doi:10.1155/2016/8163803 · Cited by 129 · see citing works
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123 · see citing works
Self-citationCianferoni, A. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.02.012 · Cited by 115 · see citing works
Broesby‐Olsen, S., Vestergaard, H., Mortz, C. G., Jensen, B., Havelund, T., Hermann, A. P., Siebenhaar, F., Møller, M. B., Kristensen, T. K., Bindslev‐Jensen, C., et al. (2018) · Allergy · doi:10.1111/all.13237 · Cited by 112 · see citing works
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., Gundabolu, K., Hobbs, G., Jamieson, C., McMahon, B., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0088 · Cited by 106 · see citing works
Pardanani, A. (2013) · Blood · doi:10.1182/blood-2013-01-453183 · Cited by 101 · see citing works
Kontou-Fili, K. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01604.x · Cited by 98 · see citing works
El‐Qutob, D. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8490-y · Cited by 97 · see citing works
Mastocytosis in Children: A Protocol for Management
Heide, R., Beishuizen, A., de Groot, H., den Hollander, J. C., van Doormaal, J. J., de Monchy, J. G. R., Pasmans, S. G. M. A., Gysel, D. V., Oranje, A. P., & ON BEHALF OF THE DUTCH NATIONAL MASTOCYTOSIS WORK GROUP (2008) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2008.00738.x · Cited by 94 · see citing works
Clinical reviews in allergy and immunology
Leung, D. Y. M., Ledford, D. K., Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., et al. (2012) · Cited by 87 · see citing works
Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83 · see citing works
“Response to additional drugs, including multitargeted tyrosine kinase inhibitors (in patients with SM, such as midostaurin) and anti-IgE therapy (ie, omalizumab) may be considered an indirect sign of MCA or MCAS.(80-88) Agents targeting growth and activation of neoplastic MCs, such as KIT-targeting kinase blockers, ar…”
BackgroundSelf-citationValent, P., Akin, C., Gleixner, K. V., Sperr, W. R., Reiter, A., Arock, M., & Triggiani, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122976 · Cited by 84 · see citing works
The presence of mast cell clonality in patients with unexplained anaphylaxis
Gülen, T., Hägglund, H., Sander, B., Dahlén, B., & Nilsson, G. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12369 · Cited by 82 · see citing works
Pharmacological treatment options for mast cell activation disease
Molderings, G. J., Haenisch, B., Brettner, S., Homann, J., Menzen, M., Dumoulin, F. L., Panse, J., Butterfield, J. H., & Afrin, L. B. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1247-1 · Cited by 77 · see citing works
Özdemir, C., Akdiş, M., & Akdiş, C. A. (2010) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000315936 · Cited by 77 · see citing works
Omalizumab in the treatment of adult patients with mastocytosis: A systematic review
Jendoubi, F., Gaudenzio, N., Gallini, A., Negretto, M., Paul, C. F., & Livideanu, C. B. (2020) · Clinical & Experimental Allergy · doi:10.1111/cea.13592 · Cited by 76 · see citing works
Mechanisms of human drug-induced anaphylaxis
Bruhns, P., & Chollet‐Martin, S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.02.013 · Cited by 76 · see citing works
Gülen, T., Hägglund, H., Dahlén, B., & Nilsson, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12410 · Cited by 75 · see citing works
Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
Lieberman, P., & Chehade, M. (2012) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0316-x · Cited by 74 · see citing works
Carter, M. C., Metcalfe, D. D., Matito, A., Escribano, L., Butterfield, J. H., Schwartz, L. B., Bonadonna, P., Zanotti, R., Triggiani, M., Castells, M., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.063 · Cited by 72 · see citing works
Self-citationOmalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS
Lemal, R., Fouquet, G., Terriou, L., Vaes, M., Livideanu, C. B., Frenzel, L., Barete, S., Canioni, D., Lhermitte, L., Rossignol, J., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.039 · Cited by 70 · see citing works
Sokol, K. C., Ghazi, A. I., Kelly, B. C., & Grant, J. A. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.03.009 · Cited by 69 · see citing works
Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient
Douglass, J. A., Carroll, K., Voskamp, A. L., Bourke, P., Wei, A. H., & O’Hehir, R. E. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02259.x · Cited by 66 · see citing works
Treatment Strategies in Mastocytosis
Siebenhaar, F., Akin, C., Bindslev‐Jensen, C., Maurer, M., & Broesby‐Olsen, S. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.01.012 · Cited by 64 · see citing works
Peter, B., Winter, G. E., Blatt, K., Bennett, K. L., Stefanzl, G., Rix, U., Eisenwort, G., Hadzijusufovic, E., Gridling, M., Dutreix, C., et al. (2016) · Leukemia · doi:10.1038/leu.2015.242 · Cited by 63 · see citing works
Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases
Molderings, G. J., Raithel, M., Kratz, F., Azémar, M., Haenisch, B., Harzer, S., & Homann, J. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4640 · Cited by 63 · see citing works
Pathogenesis and Pathology of Mastocytosis
Metcalfe, D. D., & Mekori, Y. A. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100312 · Cited by 60 · see citing works
Self-citationSuccessful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy
Siebenhaar, F., Kühn, W., Zuberbier, T., & Maurer, M. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.05.011 · Cited by 57 · see citing works
Mast cell activation disorders
Akin, C. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.03.007 · Cited by 56 · see citing works
Venom Immunotherapy in Patients with Mastocytosis and Hymenoptera Venom Anaphylaxis
González‐de‐Olano, D., Álvarez‐Twöse, I., Vega, A., Órfão, A., & Escribano, L. (2011) · Immunotherapy · doi:10.2217/imt.11.44 · Cited by 56 · see citing works
Anti-IgE – emerging opportunities for Omalizumab
Babu, K. S., Polosa, R., & Morjaria, J. B. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.782391 · Cited by 55 · see citing works
Mastocytosis and Mast Cell Activation Disorders: Clearing the Air
Jackson, C. W., Pratt, C. M., Rupprecht, C. P., Pattanaik, D., & Krishnaswamy, G. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011270 · Cited by 55 · see citing works
Omalizumab, an anti-immunoglobulin E antibody: state of the art
Incorvaia, C., Mauro, M., Russello, M., Formigoni, C., Ridolo, E., & Riario-Sforza (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s49409 · Cited by 55 · see citing works
Kontou-Fili, K., & Filis, C. I. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02045.x · Cited by 54 · see citing works
Assessing anaphylactic risk? Consider mast cell clonality
Metcalfe, D. D., & Schwartz, L. B. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.02.003 · Cited by 52 · see citing works
Self-citationAnaphylaxis as a clinical manifestation of clonal mast cell disorders
Matito, A., Alvarez-Twose, I., Morgado, J. M., Sánchez-Muñoz, L., Orfao, A., & Escribano, L. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0450-8 · Cited by 51 · see citing works
Anaphylaxis and Mast Cell Disorders
Gülen, T., & Akin, C. (2022) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.09.007 · Cited by 51 · see citing works
Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab
Bell, M. C., & Jackson, D. J. (2012) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2012.02.021 · Cited by 50 · see citing works
Kibsgaard, L., Skjold, T., Deleuran, M. S., & Vestergaard, C. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-1687 · Cited by 50 · see citing works
Mastocytosis: update on pharmacotherapy and future directions
Cardet, J. C., Akin, C., & Lee, M. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.824424 · Cited by 49 · see citing works
Brockow, K., & Metcalfe, D. D. (2010) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000315946 · Cited by 49 · see citing works
Self-citationDoctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction
Valent, P., & Akin, C. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.11.045 · Cited by 47 · see citing works
Bilò, M. B., Martini, M., Tontini, C., Corsi, A., & Antonicelli, L. (2020) · European Annals of Allergy and Clinical Immunology · doi:10.23822/eurannaci.1764-1489.158 · Cited by 47 · see citing works
Kontou-Fili, K., Filis, C. I., Voulgari, C., & Panayiotidis, P. G. (2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.04.011 · Cited by 47 · see citing works
Natural history and treatment of cutaneous and systemic mastocytosis
Le, M., Miedzybrodzki, B., Olynych, T., Chapdelaine, H., & Ben‐Shoshan, M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1364124 · Cited by 44 · see citing works
Mast cell activation syndromes presenting as anaphylaxis
Akin, C. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.01.010 · Cited by 43 · see citing works
Successful treatment of idiopathic anaphylaxis in an adolescent
Pitt, T. J., Cisneros, N., Kalicinsky, C., & Becker, A. B. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.05.043 · Cited by 43 · see citing works
Successful treatment of exercise-induced anaphylaxis with omalizumab
Bray, S. M., Fajt, M. L., & Petrov, A. A. (2012) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2012.07.021 · Cited by 43 · see citing works
Asthma and autoimmunity: a complex but intriguing relation
Tedeschi, A., & Asero, R. (2008) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.4.6.767 · Cited by 43 · see citing works
Eosinophilia in Mast Cell Disease
Kovalszki, A., & Weller, P. F. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.01.013 · Cited by 42 · see citing works
Immunology and clinical manifestations of non-clonal mast cell activation syndrome
Cardet, J.-C., Castells, M. C., & Hamilton, M. J. (2013) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0326-8 · Cited by 39 · see citing works
Promising option in the prevention of idiopathic anaphylaxis: Omalizumab
Demirtürk, M., Gelincik, A. A., Çolakoğlu, B., Murat, D. A. L., & Büyüköztürk, S. (2012) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2012.01520.x · Cited by 39 · see citing works
A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis
Carter, M. C., Marić, I., Brittain, E., Bai, Y., Lumbard, K., Bolan, H., Cantave, D., Scott, L. M., & Metcalfe, D. D. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.005 · Cited by 38 · see citing works
Self-citationMultidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus
Broesby‐Olsen, S., Dybedal, I., Gülen, T., Kristensen, T. K., Møller, M. B., Ackermann, L., Sääf, M., Karlsson, M., Agertoft, L., Brixen, K., et al. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-2325 · Cited by 38 · see citing works
Idiopathic anaphylaxis yardstick
Carter, M. C., Akin, C., Castells, M., Scott, E. P., & Lieberman, P. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.08.024 · Cited by 37 · see citing works
Self-citationPhenotypes, endotypes and biomarkers in anaphylaxis: current insights
Sala-Cunill, A., Guilarte, M., & Cardona, V. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000472 · Cited by 36 · see citing works
Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis
Matito, A., Goñi, C. B., Morgado, J. M., Álvarez‐Twöse, I., Mollejo, M., Sánchez‐Muñoz, L., & Escribano, L. (2013) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2013.08.014 · Cited by 35 · see citing works
Therapeutic approach of anaphylaxis
Tanno, L. K., Álvarez‐Perea, A., & Pouessel, G. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000539 · Cited by 35 · see citing works
Omalizumab and hypersensitivity reactions
Shankar, T., & Petrov, A. A. (2012) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32835bf3f5 · Cited by 34 · see citing works
New perspectives on mechanisms underlying chronic allergic inflammation and asthma in 2007
Broide, D. H. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.06.025 · Cited by 32 · see citing works
Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis
Quintás‐Cardama, A., Jain, N., & Verstovšek, S. (2011) · Cancer · doi:10.1002/cncr.26256 · Cited by 30 · see citing works
Lieberoth, S., & Thomsen, S. F. (2015) · Case Reports in Medicine · doi:10.1155/2015/903541 · Cited by 29 · see citing works
Sicherer, S. H., & Leung, D. Y. M. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.01.032 · Cited by 29 · see citing works
Jagdis, A., & Vadas, P. (2014) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2014.05.001 · Cited by 28 · see citing works
Targeted Treatment Options in Mastocytosis
Vaes, M., Benghiat, F. S., & Hermine, O. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00110 · Cited by 27 · see citing works
Distler, M., Maul, J., Steiner, U. C., Jandus, P., Kolios, A. G. A., Murer, C., Graf, N., Seebach, J. D., Pichler, W. J., Navarini, A. A., et al. (2020) · Dermatology · doi:10.1159/000504842 · Cited by 26 · see citing works
Anti-IgE therapy: Clinical utility beyond asthma
Casale, T. B., & Stokes, J. R. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.02.016 · Cited by 26 · see citing works
Insights in Anaphylaxis and Clonal Mast Cell Disorders
González‐de‐Olano, D., & Álvarez‐Twöse, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00792 · Cited by 23 · see citing works
Actualités sur la compréhension et le traitement des mastocytoses systémiques
Georgin‐Lavialle, S., Barète, S., Suárez, F., Lepelletier, Y., Bodemer, C., Dubreuil, P. C., Lortholary, O., & Hermine, O. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.01.025 · Cited by 24 · see citing works
Guhl, G., Díaz-Ley, B., & Fernández‐Herrera, J. (2008) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(08)74612-x · Cited by 22 · see citing works
Pala, V., Rosset, F., Mastorino, L., Sciamarrelli, N., Boskovic, S., Borriello, S., Bongiovanni, E., Crespi, O., Ribero, S., & Quaglino, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110720 · Cited by 23 · see citing works
González‐de‐Olano, D., Matito, A., Órfão, A., & Escribano, L. (2016) · F1000Research · doi:10.12688/f1000research.9565.1 · Cited by 21 · see citing works
Pharmacotherapy of mast cell disorders
Gülen, T., & Akin, C. (2017) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000377 · Cited by 21 · see citing works
Paraskevopoulos, G., Sifnaios, E., Christodoulopoulos, K., Mantopoulou, F., Papakonstantis, M., & Sabaziotis, D. (2013) · PubMed · Cited by 20 · see citing works
Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis
Constantine, G. M., Bressler, P. B., Petroni, D., Metcalfe, D. D., & Carter, M. C. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.07.041 · Cited by 20 · see citing works
Self-citationSystemic Mastocytosis: Clinical Update and Future Directions
Tremblay, D. A., Carreau, N. A., Kremyanskaya, M., & Mascarenhas, J. O. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.644 · Cited by 19 · see citing works
Sánchez, J., Ramírez, R., Díez, S., Carrizosa, S. E. S., Echenique, A., Olivares, M., & Cardona, R. (2012) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2011.09.011 · Cited by 19 · see citing works
An update on mast cell disorders
Cookson, H., & Grattan, C. E. H. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-580 · Cited by 17 · see citing works
Long-Term Omalizumab use in the Treatment of Exercise-Induced Anaphylaxis
Peterson, M. R., & Coop, C. A. (2017) · Allergy & Rhinology · doi:10.2500/ar.2017.8.0204 · Cited by 17 · see citing works
Gastrointestinal Involvement in Mast Cell Activation Disorders
Hsieh, F. H. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.008 · Cited by 17 · see citing works
Efficacy of Omalizumab in Indolent Systemic Mastocytosis
Slapnicar, C., Trinkaus, M., Hicks, L., & Vadas, P. (2019) · Case Reports in Hematology · doi:10.1155/2019/3787586 · Cited by 16 · see citing works
Relevant updates in systemic mastocytosis
Coltoff, A. R., & Mascarenhas, J. O. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.04.001 · Cited by 14 · see citing works
Systemic mastocytosis: 2023 update on diagnosis and management in adults
Costa, A. N., Scalzulli, E., Carmosino, I., Capriata, M., Ielo, C., Masucci, C., Passucci, M., Martelli, M., & Breccia, M. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2221028 · Cited by 13 · see citing works
Treatment of systemic mastocytosis
Giannetti, M. P. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.06.021 · Cited by 13 · see citing works
- Authors
- Carter, M. C., Robyn, J. A., Bressler, P. B., Walker, J. C., Shapiro, G. G., & Metcalfe, D. D.
- Affiliations
- National Institutes of Health (US)
- Allergy, Asthma and Clinical Research Center (US)
- University of Washington (US)
- Corresponding author
- Carter, Melody C.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2007-06
- Volume
- 119
- Issue
- 6
- Pages
- 1550-1551
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2061452912
- Cited by
- 172
- References
- 4
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 2 · 2023: 5 · 2022: 1 · 2021: 14 · 2020: 8 · 2019: 17 · 2018: 9 · 2017: 12 · 2016: 7 · 2015: 12 · 2014: 13 · 2013: 12 · 2012: 9
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Keywords
- omalizumab, systemic mastocytosis, urticaria pigmentosa, anti-IgE therapy, mast cell activation, c-kit D816V mutation, hypotension, mast cell proliferation, mast cell survival, mast cell mediators, mast cell degranulation
- MeSH terms
- Omalizumab, Adolescent, Anaphylaxis, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Humans, Male, Middle Aged, Urticaria Pigmentosa, Receptors, IgE, Anti-Allergic Agents, Mastocytosis, Systemic, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
